Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Reimondo

Showing results (1-10 of 82) with videos related to

Pageof 9
Sort By:
Annals of Internal Medicine|June 25, 2019
Insights on the Natural History of Adrenal IncidentalomasMassimo Terzolo, Giuseppe Reimondo
Archives of Internal Medicine|April 16, 2003
Desmopressin test in mild Cushing syndromeMassimo Terzolo, Giuseppe Reimondo, Alberto Angeli
Journal of Endocrinological Investigation|November 9, 2024
Correction: Who and how to screen for endogenous hypercortisolism in type 2 diabetes mellitus or obesityValentina Guarnotta, Carla Giordano, Giuseppe Reimondo
Archives of Medical Research|September 29, 2024
Response to: Serendipitous Adrenal Hyperplasia in Patients Admitted to the Emergency Department is Linked to Increased MortalityGiuseppe Reimondo, Soraya Puglisi, Massimo Terzolo
European Journal of Endocrinology|August 21, 2009
Definition of an optimal strategy to evaluate and follow-up adrenal incidentalomas: time for further researchMassimo Terzolo, Giuseppe Reimondo, Alberto Angeli
Journal of Endocrinological Investigation|October 1, 2024
Who and how to screen for endogenous hypercortisolism in type 2 diabetes mellitus or obesityValentina Guarnotta, Carla Giordano, Giuseppe Reimondo
Pituitary|September 1, 2005
Subclinical Cushing's syndromeMassimo Terzolo, Giuseppe Reimondo, Silvia Bovio, et al.
Minerva Endocrinologica|July 3, 2018
Autonomous hypercortisolism: definition and clinical implicationsGiuseppe Reimondo, Soraya Puglisi, Anna Pia, et al.
Endocrinology and Metabolism (Seoul, Korea)|March 25, 2020
Is Follow-up of Adrenal Incidentalomas Always Mandatory?Giuseppe Reimondo, Alessandra Muller, Elisa Ingargiola, et al.
Endocrine, Metabolic & Immune Disorders Drug Targets|July 9, 2021
Multiple Rebound-Associated Vertebral Fractures after Denosumab Discontinuation: Is Prompt Antiresorptive Therapy Always Recommended,Even When the Risk of Fracture Seems Low? A Case ReportGiangiacomo Osella, Soraya Puglisi, Anna Alì, et al.
Pageof 9

Showing results (1-10 of 82) with videos related to

Sort By:
Pageof 9
Annals of Internal Medicine|June 25, 2019
Insights on the Natural History of Adrenal IncidentalomasMassimo Terzolo, Giuseppe Reimondo
Archives of Internal Medicine|April 16, 2003
Desmopressin test in mild Cushing syndromeMassimo Terzolo, Giuseppe Reimondo, Alberto Angeli
Journal of Endocrinological Investigation|November 9, 2024
Correction: Who and how to screen for endogenous hypercortisolism in type 2 diabetes mellitus or obesityValentina Guarnotta, Carla Giordano, Giuseppe Reimondo
Archives of Medical Research|September 29, 2024
Response to: Serendipitous Adrenal Hyperplasia in Patients Admitted to the Emergency Department is Linked to Increased MortalityGiuseppe Reimondo, Soraya Puglisi, Massimo Terzolo
European Journal of Endocrinology|August 21, 2009
Definition of an optimal strategy to evaluate and follow-up adrenal incidentalomas: time for further researchMassimo Terzolo, Giuseppe Reimondo, Alberto Angeli
Journal of Endocrinological Investigation|October 1, 2024
Who and how to screen for endogenous hypercortisolism in type 2 diabetes mellitus or obesityValentina Guarnotta, Carla Giordano, Giuseppe Reimondo
Pituitary|September 1, 2005
Subclinical Cushing's syndromeMassimo Terzolo, Giuseppe Reimondo, Silvia Bovio, et al.
Minerva Endocrinologica|July 3, 2018
Autonomous hypercortisolism: definition and clinical implicationsGiuseppe Reimondo, Soraya Puglisi, Anna Pia, et al.
Endocrinology and Metabolism (Seoul, Korea)|March 25, 2020
Is Follow-up of Adrenal Incidentalomas Always Mandatory?Giuseppe Reimondo, Alessandra Muller, Elisa Ingargiola, et al.
Endocrine, Metabolic & Immune Disorders Drug Targets|July 9, 2021
Multiple Rebound-Associated Vertebral Fractures after Denosumab Discontinuation: Is Prompt Antiresorptive Therapy Always Recommended,Even When the Risk of Fracture Seems Low? A Case ReportGiangiacomo Osella, Soraya Puglisi, Anna Alì, et al.
Pageof 9